Published in Surgery on December 01, 2010
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene (2013) 0.97
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer. Onco Targets Ther (2013) 0.95
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. J Natl Cancer Inst (2014) 0.90
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab (2015) 0.89
Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget (2014) 0.86
Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget (2015) 0.84
Translational research in endocrine surgery. Surg Oncol Clin N Am (2013) 0.81
Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer. Cancer Lett (2015) 0.81
Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer (2015) 0.80
Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis. Oncotarget (2015) 0.79
SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways. Oncotarget (2015) 0.78
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid (2014) 0.78
Identification of insertions in PTEN and TP53 in anaplastic thyroid carcinoma with angiogenic brain metastasis. Endocr Relat Cancer (2015) 0.75
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening. Oncotarget (2015) 0.75
Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett (2015) 0.75
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev (2007) 5.21
Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol (2006) 2.40
Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer (1990) 2.01
Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res (2007) 1.80
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab (2009) 1.59
Anaplastic thyroid cancer. Curr Opin Oncol (2003) 1.54
Anaplastic thyroid cancer. Endocrinol Metab Clin North Am (2008) 1.54
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 1.53
BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol (2004) 1.27
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Molecular genetics of human thyroid neoplasms. Annu Rev Med (1994) 1.01
Anaplastic thyroid carcinoma in a young woman: a rare case of survival. Thyroid (2009) 0.90
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Sigmoidectomy syndrome? Patients' perspectives on the functional outcomes following surgery for diverticulitis. Dis Colon Rectum (2012) 3.28
Chilaiditi syndrome: a rare entity with important differential diagnoses. Gastroenterol Hepatol (N Y) (2012) 2.27
Identification of surgical complications and deaths: an assessment of the traditional surgical morbidity and mortality conference compared with the American College of Surgeons-National Surgical Quality Improvement Program. J Am Coll Surg (2006) 2.07
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A (2008) 1.97
Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A (2013) 1.89
Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery (2005) 1.76
The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr (2002) 1.68
Tissue-engineered small intestine improves recovery after massive small bowel resection. Ann Surg (2004) 1.64
A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid (2009) 1.53
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res (2011) 1.47
Carcinoid tumors in the breast. Am J Surg (2006) 1.41
Primary hyperparathyroidism after Roux-en-Y gastric bypass. Obes Surg (2015) 1.39
Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res (2004) 1.31
Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J (2009) 1.29
Enterocyte differentiation marker intestinal alkaline phosphatase is a target gene of the gut-enriched Kruppel-like factor. Am J Physiol Gastrointest Liver Physiol (2003) 1.29
Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist (2011) 1.27
AACE/ACE disease state commentary: molecular diagnostic testing of thyroid nodules with indeterminate cytopathology. Endocr Pract (2014) 1.24
Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis (2011) 1.18
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta (2009) 1.18
Identification of specific targets for the gut mucosal defense factor intestinal alkaline phosphatase. Am J Physiol Gastrointest Liver Physiol (2010) 1.17
A role for intestinal alkaline phosphatase in the maintenance of local gut immunity. Dig Dis Sci (2010) 1.17
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology (2011) 1.13
Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate. Thyroid (2012) 1.03
Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun (2003) 1.02
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.00
BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery (2012) 0.99
A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res (2009) 0.99
Hemorrhagic cholecystitis simulating gallbladder carcinoma. J Ultrasound Med (2004) 0.99
The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? Oncotarget (2010) 0.98
Intestinal alkaline phosphatase inhibits the proinflammatory nucleotide uridine diphosphate. Am J Physiol Gastrointest Liver Physiol (2013) 0.98
Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res (2007) 0.97
Best cases from the AFIP: paraganglioma of the organs of Zuckerkandl. Radiographics (2003) 0.96
Clinical and cytological features predictive of malignancy in thyroid follicular neoplasms. Thyroid (2010) 0.96
The thyroid incidentaloma: an increasingly frequent consequence of radiologic imaging. Semin Ultrasound CT MR (2005) 0.95
The vascular permeabilizing factors histamine and serotonin induce angiogenesis through TR3/Nur77 and subsequently truncate it through thrombospondin-1. Blood (2013) 0.93
The pro-inflammatory cytokines, IL-1beta and TNF-alpha, inhibit intestinal alkaline phosphatase gene expression. DNA Cell Biol (2006) 0.93
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.93
Antiangiogenic treatment with the three thrombospondin-1 type 1 repeats recombinant protein in an orthotopic human pancreatic cancer model. Clin Cancer Res (2005) 0.92
Thyroid surgery in octogenarians is associated with higher complication rates. Surgery (2009) 0.92
Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol (2012) 0.91
Factors associated with conversion to laparotomy in patients undergoing laparoscopic appendectomy. J Am Coll Surg (2002) 0.90
Summary statement: utility of molecular marker testing in thyroid cancer. Surgery (2010) 0.90
Hyalinizing trabecular adenoma--an uncommon thyroid tumor frequently misdiagnosed as papillary or medullary thyroid carcinoma. Am J Surg (2007) 0.89
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab (2015) 0.89
Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens. Ann Surg (2014) 0.88
Management of thyroid incidentalomas. Surg Clin North Am (2004) 0.88
Thyroid incidentalomas: a new epidemic. Curr Surg (2004) 0.88
Accuracy of 4-dimensional computed tomography in poorly localized patients with primary hyperparathyroidism. Surgery (2010) 0.88
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. Endocr Relat Cancer (2012) 0.87
Enterocyte response to ischemia is dependent on differentiation state. J Gastrointest Surg (2002) 0.87
Small bowel adenocarcinoma at a strictureplasty site in a patient with Crohn's disease: report of a case. Dis Colon Rectum (2004) 0.87
Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy. Thyroid (2003) 0.86
Intestinal alkaline phosphatase gene expression is activated by ZBP-89. Am J Physiol Gastrointest Liver Physiol (2005) 0.86
Differential regulation of intestinal alkaline phosphatase gene expression by Cdx1 and Cdx2. Am J Physiol Gastrointest Liver Physiol (2005) 0.86
Possible overuse of 3-stage procedures for active ulcerative colitis. JAMA Surg (2013) 0.85
Resident/fellow assistance in the operating room for endocrine surgery in the era of fellowships. Surgery (2010) 0.85
A novel approach to maintain gut mucosal integrity using an oral enzyme supplement. Ann Surg (2014) 0.85
Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Lett (2006) 0.85
Angiogenesis in benign and malignant thyroid disease. Thyroid (2005) 0.84
Perianal problems in patients with ulcerative colitis. Inflamm Bowel Dis (2005) 0.83
Thyroid hormone positively regulates the enterocyte differentiation marker intestinal alkaline phosphatase gene via an atypical response element. Mol Endocrinol (2004) 0.83
Local peritoneal irrigation with intestinal alkaline phosphatase is protective against peritonitis in mice. J Gastrointest Surg (2011) 0.83
Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas. Arch Surg (2007) 0.83
Convergence of the thyroid hormone and gut-enriched Krüppel-like factor pathways in the context of enterocyte differentiation. J Gastrointest Surg (2003) 0.83
Medical and surgical risks in thyroid surgery: lessons from the NSQIP. Ann Surg Oncol (2011) 0.82
Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. Am J Surg (2010) 0.82
Transcriptional activation of the enterocyte differentiation marker intestinal alkaline phosphatase is associated with changes in the acetylation state of histone H3 at a specific site within its promoter region in vitro. J Gastrointest Surg (2003) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Bilaterality in papillary thyroid carcinoma: does it influence prognosis? Ann Surg Oncol (2012) 0.81
Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. Surgery (2013) 0.81
Preoperative localization strategies for primary hyperparathyroidism: an economic analysis. Ann Surg Oncol (2012) 0.81
Multiple signaling is involved in endostatin-mediated apoptosis in ECV 304 endothelial cells. Front Biosci (2005) 0.80
Diagnostic yield of nondiagnostic thyroid nodules is not altered by timing of repeat biopsy. Thyroid (2012) 0.80
Improved eukaryotic promoter-detection vector carrying two luciferase reporter genes. Biotechniques (2003) 0.80
The effect of neoadjuvant chemoradiation therapy on the prognostic value of lymph nodes after rectal cancer surgery. Am J Surg (2010) 0.79
A 'Swinging Cradle' model for in vitro classification of different types of response elements of a nuclear receptor. Biochem Biophys Res Commun (2005) 0.79
Effect of laparoscopy on the indications for adrenalectomy. Arch Surg (2009) 0.79
Neuroendocrine tumors of the pancreas, excluding gastrinoma. Surg Oncol Clin N Am (2006) 0.78
CT predictors of failed laparoscopic appendectomy. Radiology (2003) 0.78
The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma. Thyroid (2014) 0.78
pFRL7: an ideal vector for eukaryotic promoter analysis. Anal Biochem (2006) 0.78
The Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel. Acta Cytol (2016) 0.77